Register entry
- Registered sites
- 1
- Active NDC listings
- 3
- Live patents
- 7
- Exclusivities
- 1
- Shortage listings
- 1
- Countries
- 1
- Base
- United States
Authorisation
Registered operations
Analytical testing1Labelling1Finished drug manufacture1Packaging1
Sites
Registered establishments
1| Establishment | Address | Registered for | FEI / DUNS |
|---|---|---|---|
| Glaukos Corporation | 229, 236 Avenida Fabricante, San Clemente, California (CA) 92672, United States (USA) | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3012341472080653551 |
Alert
Drug shortage listings
1| Drug | Presentation | Status | Availability | Posted / updated |
|---|---|---|---|---|
| Riboflavin 5-phosphate Ophthalmic SolutionOphthalmology | Photrexa Cross-linking Kit, Ophthalmic Solution, Kit (NDC 25357-025-03) | To Be Discontinued | - | 20 Jan 202620 Jan 2026 |
Catalogue
Drug listings by form and route
33 active NDC listings: 3 human prescription drug. By marketing category: NDA 3.
| Dosage form | NDCs |
|---|---|
| kit | 2 |
| implant | 1 |
| Route | NDCs |
|---|---|
| intracameral | 1 |
| ophthalmic | 1 |
| Labeller name on the listing | NDCs |
|---|---|
| glaukos corporation | 3 |
Exclusivity
Patents and exclusivities
7| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 9539241 | MITOSOLmitomycin | substance, product | Jan 2028 |
| 7806265 | MITOSOLmitomycin | product | Feb 2029 |
| 9649428 | MITOSOLmitomycin | use | May 2029 |
| 12201557 | IDOSE TRtravoprost | substance, product | Jun 2030 |
| 10206813 | IDOSE TRtravoprost | product | Oct 2030 |
| 11426306 | IDOSE TRtravoprost | product | Oct 2030 |
| 12201555 | IDOSE TRtravoprost | substance, product | Feb 2031 |
| Product | Exclusivity | Until |
|---|---|---|
| IDOSE TRTRAVOPROST | NP New product | Dec 2026 |
Catalogue
Marketed products
3| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| EPIOXA CROSS-LINKING | riboflavin 5-phosphate ophthalmic | kit, ophthalmic | 25357-024NDA |
| Photrexa Cross-linking Kit | riboflavin 5-phosphate ophthalmic | kit | 25357-025NDA |
| iDose TR | Travoprost Intracameral | implant, intracameral | 25357-100NDA |
Compare
Comparable companies in United States
- Hahnemann Laboratories, Inc. dba Alpine Pharmaceuticals1 site · 4,853 NDC
- NuCare Pharmaceuticals,Inc.1 site · 1,393 NDC
- Greer Laboratories, Inc.1 site · 1,328 NDC
- ASCLEMED USA INC. DBA ENOVACHEM1 site · 789 NDC
- Golden State Medical Supply Inc.1 site · 670 NDC
- Rising Pharma Holdings, Inc.1 site · 532 NDC
- HF Acquisition Co LLC1 site · 363 NDC
- ANI Pharmaceuticals, Inc.1 site · 299 NDC
- Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.1 site · 273 NDC
- Newton Laboratories, Inc.1 site · 271 NDC
Enquiry
Common questions
- Is Glaukos Corporation FDA approved?
- Glaukos Corporation holds 1 FDA-registered establishment in the United States. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
- Where are Glaukos Corporation's drugs manufactured?
- The FDA register lists San Clemente, CA. Registered operations: analytical testing, labelling, finished drug manufacture, packaging.
- What drugs does Glaukos Corporation make?
- 3 products are listed under Glaukos Corporation in the openFDA NDC Directory, most often as kit; implant. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.